Results 201 to 210 of about 45,606 (277)

Redox environment modulates aggregation of ataxin‐3 in vitro — Implications for drug screening of cysteine‐rich proteins

The FEBS Journal, Volume 293, Issue 11, Page 3376-3398, June 2026.
Redox environment modulates in vitro aggregation of Ataxin‐3, the protein implicated in spinocerebellar ataxia type 3. Reducing conditions stabilize native monomers and prevent aggregation, whereas oxidative conditions promote the formation of non‐native conformers and disulfide‐linked oligomers within the Josephin domain (JD).
Martyna Podlasiak, Martina Sollazzo, Elisa Monaca, Raffaele Sabbatella, Maria Agnese Morando, Oleg Chertkov, Laura Puglisi, Martina Mascellino, Anna Fricano, Sandra Macedo‐Ribeiro, Caterina Alfano   +10 more
wiley   +1 more source

Prion diseases: Lessons from historical outbreaks and potential emerging ones. [PDF]

Protein Sci
Holman AP, Kurouski D.
europepmc   +1 more source

Issue Information

Brain Pathology, Volume 36, Issue 4, July 2026.
wiley   +1 more source

Investigating Disordered Eating Behaviours Among Individuals Living With Neurodegenerative Disease: A Scoping Review

Journal of Human Nutrition and Dietetics, Volume 39, Issue 3, June 2026.
ABSTRACT Aim Neurodegenerative diseases and disordered eating have become rapidly expanding areas of research. However, research addressing the relationship between the two is lacking. Methods A scoping review guided by the Joanna Briggs Institute methodological framework was completed to synthesise the evidence related to disordered eating behaviours ...
Emily Buttifant, Shoroog Allogmanny, Yasmine Probst   +2 more
wiley   +1 more source

Therapeutic perspectives for prion diseases in humans and animals. [PDF]

PLoS Pathog
Benavente R, Morales R.
europepmc   +1 more source

Effects of Lysine Deacetylation Inhibition Alone or in Combination With Arimoclomol on TDP‐43 Proteinopathy

Journal of Neurochemistry, Volume 170, Issue 6, June 2026.
TDP‐43 pathology is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Peptidyl‐prolyl cis–trans isomerase A (PPIA), a foldase and chaperone protein, modulates TDP‐43 function in an acetylation‐dependent manner. Here, we show that inhibition of lysine deacetylation with vorinostat (SAHA) increases PPIA acetylation and ...
Serena Scozzari, Stefano Fabrizio Columbro, Monica Favagrossa, Massimo Tortarolo, Alfredo Cagnotto, Mario Salmona, Giovanni De Marco, Caterina Bendotti, Andrea Calvo, Laura Pasetto, Valentina Bonetto   +10 more
wiley   +1 more source

Development of a user guide to support administration of the MRC Prion Disease Rating Scale in research and clinical settings for prion diseases. [PDF]

Prion
Pulido RS, Marshall C, Smith AV, Edge H, Yarlas A, Appleby B, Brandel JP, Collins S, Omer N, Zerr I, Mead S.   +10 more
europepmc   +1 more source

'Prion' Diseases

Journal of the Royal College of Physicians of London, 1994
openaire   +2 more sources

Understanding the Phenotypic Heterogeneity Within the Sporadic Creutzfeldt–Jakob Disease MV1 Subtype

Neuropathology and Applied Neurobiology, Volume 52, Issue 3, June 2026.
We present the clinical, pathological and prion biophysical features of three atypical cases of the MV1 subtype of sporadic Creutzfeldt–Jakob disease (sCJD). We propose that these heterozygous cases exist on a spectrum ranging from MM1‐like to VV1‐like phenotypes and recommend that subtyping be performed at pH 6.9 to avoid missing atypical or mixed ...
Satish K. Nemani, Leonardo M. Cortez, Jennifer Myskiw, Ignazio Cali, Stephanie A. Booth, Gerard H. Jansen, Valerie L. Sim   +6 more
wiley   +1 more source

Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases. [PDF]

Acta Pharmacol Sin
Mukherjee A, Biswas S, Roy I.
europepmc   +1 more source